5 Stocks with 50% Upside Potential According to Analysts

2. Royalty Pharma plc (NASDAQ:RPRX)

Market Capitalization as of December 8: $17.16 Billion
Stock Upside Potential: 69%
Number of Hedge Fund Holders: 31 

Based in New York, Royalty Pharma plc (NASDAQ:RPRX) is a buyer of biopharmaceutical royalties and a funder in the biopharmaceutical industry. The company identifies, evaluates, and acquires royalties on various biopharmaceutical therapies. 

Royalty Pharma plc (NASDAQ:RPRX) collaborates with academic institutions, research hospitals, and not-for-profits to acquire therapies and development-stage product candidates. A big chunk of Royalty Pharma plc (NASDAQ:RPRX) revenue comes from fibrosis drugs. The company provides investors with an attractive dividend yield of 2.6%, significantly higher than the S&P 500 average of 1.5%. The stock is rated as a Buy with a $48.75 price target, implying 69% upside potential.

As of the end of the third quarter of 2023, 31 hedge funds tracked by Insider Monkey had stakes in Royalty Pharma plc (NASDAQ:RPRX). The biggest stakeholder of Royalty Pharma plc (NASDAQ:RPRX) during this period was Phill Gross and Robert Atchinson’s Adage Capital Management, which owns a $267.06 million stake in the company.

Follow Royalty Pharma Plc (NASDAQ:RPRX)

[/company-follow-email]